# A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression

> **NCT07431216** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Starlight Therapeutics Inc.** · enrollment: 68 (estimated)

## Conditions studied

- Glioblastoma (GBM)

## Interventions

- **DRUG:** STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle.
- **DRUG:** Spironolactone (drug)

## Key facts

- **NCT ID:** NCT07431216
- **Lead sponsor:** Starlight Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07431216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07431216, "A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07431216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*